#Class Action #Securities Fraud #ADMA Biologics

Investors Have a Chance to Lead a Class Action Against ADMA Biologics

In the world of investment, opportunities for legal recourse can arise unexpectedly, especially when companies are alleged to have misled their stakeholders. Robbins Geller Rudman & Dowd LLP, a prominent law firm specializing in securities fraud, has announced a significant announcement for investors in ADMA Biologics, Inc. (NASDAQ: ADMA). Investors who have incurred substantial losses while holding ADMA Biologics securities between August 9, 2024, and March 25, 2026, now have until August 10, 2026, to seek appointment as lead plaintiff in a class action lawsuit against the company.

Understanding the Class Action Lawsuit

The case, titled Mazzarino v. ADMA Biologics, Inc., No. 26-cv-06918 (D.N.J.) is poised to address serious allegations against ADMA Biologics and certain executive officers. The accusations include violations of the Securities Exchange Act of 1934, based on claims that the company failed to disclose critical information. Specifically, the lawsuit alleges that during the class period, ADMA Biologics engaged in undisclosed related party transactions and manipulated their revenue reporting through channel stuffing practices  methods that inappropriately inflated the appearance of their financial strength.

The Allegations of Misleading Information

On March 24, 2026, the situation intensified when Culper Research published a report suggesting that the reported growth of ADMA Biologics was